XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies
Transaction Positions XTL at the Forefront of the Rapidly Expanding Global Psychedelic…
Servier completes the acquisition of Day One Biopharmaceuticals
Acquisition expands Servier's position in oncology with tovorafenib marketed as OJEMDATM in the…
Provectus Biopharmaceuticals Highlights Preclinical Evidence of PV-10-Mediated Immune Modulation in Burn Wound Healing; Porcine Study Demonstrates Shift Toward Pro-Regenerative Tissue Environment
KNOXVILLE, Tenn., April 02, 2026 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus”…
XTL Biopharmaceuticals Announces ADS Ratio Change
March 20, 2026 16:10 ET | Source: XTL Biopharmaceuticals Ltd. RAMAT GAN,…
Servier and Day One Biopharmaceuticals announce acquisition to expand Servier’s rare oncology portfolio
Acquisition positions Servier as a leader in pediatric low-grade glioma and expands…
Dr. Falk Pharma and Allianthera (Suzhou) Biopharmaceuticals Forge Strategic Partnership for Novel AhR Agonist Development
Freiburg (Germany), Suzhou (China) and Boston (USA), July 30, 2025: Dr. Falk…
Provectus Biopharmaceuticals Announces Investor Webinar for 2025 Annual Meeting of Stockholders
KNOXVILLE, Tenn., June 09, 2025 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus”…
